Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-03-04
Target enrollment:
Participant gender:
Summary
This open-label Phase 2 study will evaluate the safety and efficacy of modified T cells
(JCAR017) administered to adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL).
The study will also help determine how long the modified T cells stay in the patient's body.
Furthermore, changes in the patient's quality of life will be described. Phase 2 (autologous
T cells expressing anti-CD19 chimeric antigen receptor) (DLBCL NOS [de novo or tFL],
follicular lymphoma Grade 3B [FL3B], high grade B-cell Lymphoma [HGBL] and primary central
nervous system lymphoma [PCNSL]).